From Insulin to GLP-1s — a Peptide Saga: The Drugs That Shape Us, Episode 4
If you’re on social media, you may feel bombarded by influencers promoting peptides for a range of ailments so broad it almost seems like a brand-new trend. But peptide-based therapies actually date back to 1922, when insulin was first administered to treat diabetes. But it wasn’t until semaglutide (better known as Ozempic) entered the market that peptides truly captured public attention. In today’s episode, we explore how what chemists and other scientists learned from insulin paved the way for the remarkable effectiveness of GLP-1 drugs, and how treatments originally developed for diabetes are now being used to address obesity, substance use, and more.
Transcripts and episode sources at acs.org/chainreaction
More description
If you’re on social media, you may feel bombarded by influencers promoting peptides for a range of ailments so broad it almost seems like a brand-new trend. But peptide-based therapies actually date back to 1922, when insulin was first administered to treat diabetes. But it wasn’t until semaglutide (better known as Ozempic) entered the market that peptides truly captured public attention. In today’s episode, we explore how what chemists and other scientists learned from insulin paved the way for the remarkable effectiveness of GLP-1 drugs, and how treatments originally developed for diabetes are now being used to address obesity, substance use, and more.
Transcripts and episode sources at acs.org/chainreaction